Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223911 | 1.00 | CTSS (0.32) | CTSSCTSKPREPCYP2D6TRPA1 | |
| SCHEMBL19318535 | 1.00 | CTSS (0.32) | CTSSCTSKPREPCYP2D6TRPA1 | |
| SCHEMBL8906150 | 1.00 | CTSS (0.32) | CTSSCTSKPREPCYP2D6TRPA1 | |
| SCHEMBL4741986 | 1.00 | CTSS (0.32) | CTSSCTSKPREPCYP2D6TRPA1 | |
| SCHEMBL16577293 | 0.86 | CTSK (0.39) | CTSSCTSKPREPTRPA1CTSL | |
| SCHEMBL13140751 | 0.86 | CTSK (0.39) | CTSSCTSKPREPTRPA1CTSL | |
| SCHEMBL7602626 | 0.86 | CTSK (0.39) | CTSSCTSKPREPTRPA1CTSL | |
| SCHEMBL8906252 | 0.82 | CTSS (0.31) | CTSSCTSK | |
| SCHEMBL19318572 | 0.82 | CTSS (0.31) | CTSSCTSK | |
| SCHEMBL14930628 | 0.82 | CTSS (0.31) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CTSS 917/4885CTSK 2116/4885PREP 767/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CTSS 917/4885CTSK 2116/4885PREP 767/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CTSS 2582/4885CTSK 2105/4885PREP 1004/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CTSS 2638/4885CTSK 2467/4885PREP 1666/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CTSS 853/4885CTSK 1129/4885PREP 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.